Flexible Flat-Rate Plans
Flat-rate pricing for predictable budgeting
Short-term plans for project- or client-based billing
Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing
DrugPatentWatch Database Preview
VYVANSE Drug Profile
« Back to Dashboard
This drug has one hundred and forty-two patent family members in twenty-six countries.
The generic ingredient in VYVANSE is lisdexamfetamine dimesylate. Four suppliers are listed for this compound. There are five tentative approvals for this compound. Additional details are available on the lisdexamfetamine dimesylate profile page.
Summary for Tradename: VYVANSE
| Patents: | 18 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: see list | 4 |
| Drug Prices: : | see details |
Pharmacology for Tradename: VYVANSE
| Drug Class | Central Nervous System Stimulant |
| Physiological Effect | Central Nervous System Stimulation |
Clinical Trials for: VYVANSE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Type | RLD | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shire Development | VYVANSE | lisdexamfetamine dimesylate | CAPSULE;ORAL | 021977-005 | Dec 10, 2007 | RX | No | 7,223,735 | Feb 24, 2023 | Y | |||||||||||||||||||
Shire Development | VYVANSE | lisdexamfetamine dimesylate | CAPSULE;ORAL | 021977-006 | Dec 10, 2007 | RX | No | 7,723,305 | Feb 24, 2023 | Y | |||||||||||||||||||
Shire Development | VYVANSE | lisdexamfetamine dimesylate | CAPSULE;ORAL | 021977-001 | Feb 23, 2007 | RX | No | 7,671,030 | Feb 24, 2023 | Y | |||||||||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||||||||||||||||
Export unavailable in trial.
Subscribe for complete access.
Paragraph IV activity for: VYVANSE
| Drugname | Dosage | Strength | RLD | Submissiondate |
|---|---|---|---|---|
| lisdexamfetamine dimesylate | Capsules | 20 mg, 30 mg, 40 mg, 50 mg, 60 mg and 70 mg | Vyvanse | 2/23/2011 |
Non-Orange Book Patents for Tradename: VYVANSE
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
| Patent No. | Title | Estimated Patent Expiration | |||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 8,394,813 | Active agent delivery systems and methods for protecting and administering active agents | <disabled in preview> | |||||||||||||||||||||||||||
| 6,716,452 | Active agent delivery systems and methods for protecting and administering active agents | <disabled in preview> | |||||||||||||||||||||||||||
| 7,375,083 | Pharmaceutical compositions for prevention of overdose or abuse | <disabled in preview> | |||||||||||||||||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||||||||||||||||
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.
International Patent Family for Tradename: VYVANSE
| Country | Document Number | Estimated Expiration | |||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Portugal | 1644019 | <disabled in preview> | |||||||||||||||||||||||||||
| World Intellectual Property Organization (WIPO) | 2004062614 | <disabled in preview> | |||||||||||||||||||||||||||
| Germany | 60141719 | <disabled in preview> | |||||||||||||||||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||||||||||||||||
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws,
it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.
Supplementary Protection Certificates for Tradename: VYVANSE
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description | ||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 90058-4 | Sweden | <disabled> | PRODUCT NAME: LISDEXAMFETAMIN VALFRITT I FORMEN AV ETT FARMACEUTISKT GODTAGBART SALT, SAERSKILT ETT MESYLATSALT; NAT. REG. NO/DATE: 47382 20130722; FIRST REG.: GB PL 08081/0050-52 20130201 | ||||||||||||||||||||||||||
| 2013 00043 | Denmark | <disabled> | PRODUCT NAME: LISDEXAMFETAMIN, EVENTUELT I FORM AF ET FARMACEUTISK ACCEPTABELT SALT, ISAER ET MESYLAT SALT; NAT. REG. NO/DATE: MT499080, MT499081, MT499082 20130214; FIRST REG. NO/DATE: PL PL 08081/0050-0052 20130201 | ||||||||||||||||||||||||||
| 2013000079 | Germany | <disabled> | PRODUCT NAME: LISDEXAMFETAMINE ODER EIN PHARMAZEUTISCH VERTRAEGLICHES SALZ DESSEN, WIE L-LYSIN-D-AMPHETAMIN-MESYLAT; NATIONAL REGISTRATION NO/DATE: 86155-86157.00.00 20130318; FIRST REGISTRATION: GB PL 08081/0050-2 20140201 | ||||||||||||||||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||||||||||||||||
Export unavailable in trial.
Subscribe for complete access.
« Back to Dashboard
For more information try a trial or see the database preview and plans and pricing
How are People Using DrugPatentWatch?
To study exclusivity periods for a number of drugs
— Pharmaceutical company, Canada
To gain knowledge of expiry of patents in anticipation of generic/biosimilars entering the market
— Clinical pharmacist, state drug formulary committee, USA
To identify pharmaceutical product patents and process patents, and drug patent expiries
— Global pharmaceutical regulatory affairs, India
To be able to inform my clients with Part D prescription plans when a brand name drug is going off patent
— Pharmacist, USA
To know the expiration dates of several pharmaceuticals products
— Pharmaceutical company, Spain
To obtain a list of all currently off-patent approved small molecule therapeutics or those that will come off patent in the next 5 years
— Licensing / business development, Saudi Arabia
To have more information regarding the patents and generic products available
— Project manager, bioequivalence studies, Brazil
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Copyright 2002-2016 thinkBiotech LLC
ISSN: 2162-2639
